TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: Jun 2025

Income Metrics

Revenue 290.6M
Gross Profit 127.7M 43.94%
Operating Income 8.1M 2.79%
Net Income 5.6M 1.94%
EPS (Diluted) $0.12

Balance Sheet Metrics

Total Assets 2.2B
Total Liabilities 894.4M
Shareholders Equity 1.3B
Debt to Equity 0.71

Cash Flow Metrics

Operating Cash Flow 28.3M
Free Cash Flow 10.2M

Revenue & Profitability Trend

Omnicell Income Statement From 2020 to 2024

Metric20242023202220212020
Revenue i1.1B1.1B1.3B1.1B892.2M
Cost of Goods Sold i641.2M650.3M707.0M577.4M478.9M
Gross Profit i471.0M496.8M589.0M554.7M413.3M
Gross Margin % i42.3%43.3%45.4%49.0%46.3%
Operating Expenses
Research & Development i90.4M97.1M105.0M75.7M70.2M
Selling, General & Administrative i380.3M434.6M486.3M389.4M307.6M
Other Operating Expenses i-----
Total Operating Expenses i470.7M531.7M591.3M465.1M377.8M
Operating Income i337.0K-34.9M-2.3M89.5M35.5M
Operating Margin % i0.0%-3.0%-0.2%7.9%4.0%
Non-Operating Items
Interest Income i-----
Interest Expense i-----
Other Non-Operating Income-----
Pre-tax Income i25.6M-20.1M-2.5M66.0M29.3M
Income Tax i13.1M263.0K-8.1M-11.8M-2.8M
Effective Tax Rate % i51.0%0.0%0.0%-17.9%-9.7%
Net Income i12.5M-20.4M5.6M77.8M32.2M
Net Margin % i1.1%-1.8%0.4%6.9%3.6%
Key Metrics
EBITDA i90.1M60.7M96.8M174.4M107.1M
EPS (Basic) i$0.27$-0.45$0.13$1.79$0.76
EPS (Diluted) i$0.27$-0.45$0.12$1.62$0.74
Basic Shares Outstanding i4604700045212000443980004347500042583000
Diluted Shares Outstanding i4604700045212000443980004347500042583000

Income Statement Trend

Omnicell Balance Sheet From 2020 to 2024

Metric20242023202220212020
Assets
Current Assets
Cash & Equivalents i369.2M468.0M330.4M349.1M485.9M
Short-term Investments i12.5M11.9M11.5M10.7M10.2M
Accounts Receivable i256.4M252.0M299.5M240.9M190.1M
Inventory i88.7M110.1M147.5M119.9M96.3M
Other Current Assets13.6M7.7M7.5M10.6M2.5M
Total Current Assets i815.5M927.6M881.8M780.7M829.4M
Non-Current Assets
Property, Plant & Equipment i125.3M121.0M129.4M137.8M136.1M
Goodwill i1.7B1.7B1.8B1.9B1.3B
Intangible Assets i246.7M277.8M323.7M374.6M262.2M
Long-term Investments-----
Other Non-Current Assets78.3M56.7M46.6M46.4M40.3M
Total Non-Current Assets i1.3B1.3B1.3B1.4B995.1M
Total Assets i2.1B2.2B2.2B2.1B1.8B
Liabilities
Current Liabilities
Accounts Payable i51.8M45.0M63.4M71.5M40.3M
Short-term Debt i185.0M10.5M10.8M501.1M12.2M
Current Portion of Long-term Debt-----
Other Current Liabilities-----
Total Current Liabilities i595.7M367.8M428.4M876.2M276.4M
Non-Current Liabilities
Long-term Debt i197.5M603.6M606.0M39.9M516.1M
Deferred Tax Liabilities i1.1M1.6M2.1M51.7M39.6M
Other Non-Current Liabilities7.2M6.3M6.7M7.8M19.2M
Total Non-Current Liabilities i282.0M670.1M652.2M119.6M580.6M
Total Liabilities i877.6M1.0B1.1B995.8M857.0M
Equity
Common Stock i57.0K56.0K55.0K54.0K53.0K
Retained Earnings i382.9M370.4M390.7M368.6M290.7M
Treasury Stock i290.3M290.3M290.3M238.1M238.1M
Other Equity-----
Total Shareholders Equity i1.2B1.2B1.1B1.1B967.5M
Key Metrics
Total Debt i382.5M614.1M616.7M541.0M528.3M
Working Capital i219.8M559.8M453.4M-95.5M553.0M

Balance Sheet Composition

Omnicell Cash Flow Statement From 2020 to 2024

Metric20242023202220212020
Operating Activities
Net Income i12.5M-20.4M5.6M77.8M32.2M
Depreciation & Amortization i89.8M95.6M99.2M84.9M71.6M
Stock-Based Compensation i39.3M55.3M68.2M53.2M44.7M
Working Capital Changes i38.1M67.3M-92.2M-38.0M43.1M
Operating Cash Flow i168.6M191.1M47.7M196.8M191.4M
Investing Activities
Capital Expenditures i-36.5M-41.5M-47.5M-29.0M-22.8M
Acquisitions i002.1M-354.2M-225.0M
Investment Purchases i-----
Investment Sales i-----
Investing Cash Flow i-36.5M-41.5M-45.5M-383.1M-247.8M
Financing Activities
Share Repurchases i00-52.2M0-53.0M
Dividends Paid i-----
Debt Issuance i166.3M-00559.7M
Debt Repayment i-391.7M-00-200.0M
Financing Cash Flow i-274.2M204.0K-61.1M-20.0M150.7M
Free Cash Flow i134.9M126.1M17.0M173.5M131.0M
Net Change in Cash i-142.0M149.8M-58.9M-206.4M94.2M

Cash Flow Trend

Omnicell Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 66.90
Forward P/E 17.84
Price to Book 1.18
Price to Sales 1.32
PEG Ratio 1.34

Profitability Ratios

Profit Margin 2.01%
Operating Margin 2.80%
Return on Equity 1.87%
Return on Assets 0.49%

Financial Health

Current Ratio 1.42
Debt to Equity 30.42
Beta 0.82

Per Share Data

EPS (TTM) $0.48
Book Value per Share $27.22
Revenue per Share $24.74

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
omcl1.5B66.901.181.87%2.01%30.42
Veeva Systems 44.1B55.526.6613.70%27.29%1.29
Ge Healthcare 34.6B14.833.4025.80%11.22%107.67
10x Genomics 1.7B-9.182.18-11.30%-13.13%11.22
Certara 1.7B210.401.580.75%1.97%29.00
Phreesia 1.4B-5.34-22.67%-13.94%2.60

Financial data is updated regularly. All figures are in the company's reporting currency.